734 related articles for article (PubMed ID: 16530575)
21. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
[TBL] [Abstract][Full Text] [Related]
22. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Egger M; May M; Chêne G; Phillips AN; Ledergerber B; Dabis F; Costagliola D; D'Arminio Monforte A; de Wolf F; Reiss P; Lundgren JD; Justice AC; Staszewski S; Leport C; Hogg RS; Sabin CA; Gill MJ; Salzberger B; Sterne JA;
Lancet; 2002 Jul; 360(9327):119-29. PubMed ID: 12126821
[TBL] [Abstract][Full Text] [Related]
23. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes.
May M; Boulle A; Phiri S; Messou E; Myer L; Wood R; Keiser O; Sterne JA; Dabis F; Egger M;
Lancet; 2010 Aug; 376(9739):449-57. PubMed ID: 20638120
[TBL] [Abstract][Full Text] [Related]
24. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
25. Long-term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa.
Huet C; Ouedraogo A; Konaté I; Traore I; Rouet F; Kaboré A; Sanon A; Mayaud P; Van de Perre P; Nagot N
BMC Public Health; 2011 Sep; 11():700. PubMed ID: 21917177
[TBL] [Abstract][Full Text] [Related]
26. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
27. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean.
Tuboi SH; Schechter M; McGowan CC; Cesar C; Krolewiecki A; Cahn P; Wolff M; Pape JW; Padgett D; Madero JS; Gotuzzo E; Masys DR; Shepherd BE
J Acquir Immune Defic Syndr; 2009 Aug; 51(5):615-23. PubMed ID: 19430306
[TBL] [Abstract][Full Text] [Related]
28. Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort.
Servais J; Schmit JC; Arendt V; Lambert C; Staub T; Robert I; Fontaine E; Plesséria JM; Burgy C; Kirpach P; Schneider F; Hemmer R
HIV Clin Trials; 2000; 1(2):17-24. PubMed ID: 11590494
[TBL] [Abstract][Full Text] [Related]
29. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
30. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America.
; Keiser O; Anastos K; Schechter M; Balestre E; Myer L; Boulle A; Bangsberg D; Touré H; Braitstein P; Sprinz E; Nash D; Hosseinipour M; Dabis F; May M; Brinkhof MW; Egger M
Trop Med Int Health; 2008 Jul; 13(7):870-9. PubMed ID: 18373510
[TBL] [Abstract][Full Text] [Related]
31. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
32. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
33. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
34. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.
May M; Sterne JA; Sabin C; Costagliola D; Justice AC; Thiébaut R; Gill J; Phillips A; Reiss P; Hogg R; Ledergerber B; D'Arminio Monforte A; Schmeisser N; Staszewski S; Egger M;
AIDS; 2007 May; 21(9):1185-97. PubMed ID: 17502729
[TBL] [Abstract][Full Text] [Related]
35. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
[TBL] [Abstract][Full Text] [Related]
36. The TREAT Asia HIV Observational Database: baseline and retrospective data.
Zhou J; Kumarasamy N; Ditangco R; Kamarulzaman A; Lee CK; Li PC; Paton NI; Phanuphak P; Pujari S; Vibhagool A; Wong WW; Zhang F; Chuah J; Frost KR; Cooper DA; Law MG;
J Acquir Immune Defic Syndr; 2005 Feb; 38(2):174-9. PubMed ID: 15671802
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of first-line antiretroviral therapy in Latin America: analysis from the LATINA retrospective cohort study.
Angriman F; Belloso WH; Sierra-Madero J; Sánchez J; Moreira RI; Kovalevski LO; Orellana LC; Cardoso SW; Crabtree-Ramirez B; La Rosa A; Losso MH
Int J STD AIDS; 2016 Feb; 27(2):118-26. PubMed ID: 25740759
[TBL] [Abstract][Full Text] [Related]
38. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients.
Antiretroviral Therapy Cohort Collaboration
J Acquir Immune Defic Syndr; 2007 Dec; 46(5):607-15. PubMed ID: 18043315
[TBL] [Abstract][Full Text] [Related]
39. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
[TBL] [Abstract][Full Text] [Related]
40. Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD).
Oyomopito R; Lee MP; Phanuphak P; Lim PL; Ditangco R; Zhou J; Sirisanthana T; Chen YM; Pujari S; Kumarasamy N; Sungkanuparph S; Lee CK; Kamarulzaman A; Oka S; Zhang FJ; Mean CV; Merati T; Tau G; Smith J; Li PC;
HIV Med; 2010 Sep; 11(8):519-29. PubMed ID: 20345881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
